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1. Introduction
Atherosclerosis is a progressive inflamma-
tory disease characterized by the accumu-
lation of lipids, immune cells, and fibrous 
elements in the artery wall. The disease 
is highly prevalent worldwide and is the 
leading cause of morbidity and mortality in 
industrialized countries.[1,2] Currently, both 
medication and surgical intervention are 
employed to treat atherosclerosis.[3,4] Unfor-
tunately, general oral medication is limited 
to the treatment of early stage atheroscle-
rosis. Due to its nonspecific distribution 
throughout the body, oral medication usu-
ally causes adverse effects, especially after 
long-term treatment.[5,6] Although surgical 
interventions (e.g., stenting) are effective 
for the treatment of advanced atheroscle-
rosis, such procedures are associated with 
side effects such as restenosis and late stent 
thrombosis, which hampers the long-term 
success of surgical intervention.[7]
Nanotechnology promotes the specific 
delivery of therapeutic compounds and 
offers significant advantages over more tra-
ditional therapies, both in terms of efficacy 
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and safety.[8–11] However, one shortcoming of conventional 
drug delivery nanosystems is the lack of site targeting. One of 
the important mechanisms responsible for limited targeting 
is that the phagocytic system of the human body recognizes 
nanoparticles as foreign substances and this leads to fast 
clearance.[12,13] Therefore, it is critical, yet difficult, to engineer 
nanoparticles with a biomimetic natural interface that evade the 
phagocyte system but still achieve specific targeting.[14] The gold 
standard is to utilize synthetic hydrophilic and flexible polymers 
such as poly(ethylene glycol) (PEG) to modify the surface of 
the nanoparticles. Due to PEG’s highly flexible and hydrophilic 
properties, a PEG coating creates a hydration layer to effectively 
reduce undesirable protein adsorption onto the surface, evade 
immune recognition and clearance, and then prolong the blood 
circulation time to enhance targeted drug delivery by EPR 
(enhanced permeability and retention) effects.[15,16] Although 
several PEG-modified nanodelivery systems have achieved some 
success in the clinic,[17,18] it is increasingly being reported that the 
response of the immune system against the synthetic polymer, 
and the production of antibodies against PEG, potentially impair 
their performance in long-term treatment.[19,20] More recently, 
cell membrane-coated nanoparticles with highly complex func-
tionalities for effective bio-interfacing have been developed.[21–24] 
These membrane-coated nanoparticles possess high biocom-
patibility and prolonged half-life in the circulation, as well as 
exhibiting disease-specific targeting. Therefore, such membrane-
coated nanomedicines have been employed in various research 
areas, including detoxification, vaccination, cardiovascular dis-
ease, and cancer.[14,21,25–27] Various different types of membrane 
have been used to fabricate biomimetic nanoparticles. Among 
them, the red blood cell (RBC) membrane is an attractive choice 
to cloak nanoparticles because of its excellent biocompatibility, 
long half-life in the circulation (≈120 days), and outstanding 
accessibility (the most abundant cell in blood).[28–30] Indeed, 
studies have shown extended half-life in blood, enhanced pene-
tration and retention in tumor tissue when nanoparticles are 
cloaked with the RBC membrane.[26,28–31] The EPR effect also 
exists in atherosclerotic lesions based on the leaky endothe-
lium in inflammation and leaky microvessels in atherosclerotic 
plaque, allowing nanoparticles to permeate the vascular wall and 
accumulate within the pathological lesion.[32,33]
We hypothesized that coating nanoparticles with RBC mem-
branes could enable them to evade the phagocytic system by 
incorporating the “natural” properties of the RBC membrane, 
thereby achieving a long half-life in the circulation. We further 
hypothesized that loading these RBC membrane-coated nano-
particles with an antiatherosclerotic compound would treat 
atherosclerosis more effectively than uncoated nanoparticles. 
In addition, poly(lactic-co-glycolic) acid (PLGA), a material 
approved by US food and drug administration (FDA), was 
selected as an excellent biocompatible and biodegradable 
material for efficient drug loading. Rapamycin (RAP), an 
inhibitor of the mammalian target of the rapamycin (mTOR) 
pathway, has been considered to be an effective antiatheroscle-
rotic agent, in view of its multiple pharmacological activities 
including anti-inflammation, antimigration, antiproliferation, 
and autophagy activation.[34,35] Therefore, the PLGA nanoparti-
cles were loaded with RAP as a “core” structure (RAP@PLGA). 
We then coated the RAP@PLGA nanoparticles with RBC vesi-
cles (RV), extracted from RBCs, to fabricate the RBC-based 
“core–shell” structured nanocomplexes (Figure 1). In this 
study, we have shown that this strategy enhances the half-life 
of RAP@PLGA nanoparticles in the circulation. More impor-
tantly, we have shown that these biomimetic nanoparticles 
can accumulate within atherosclerotic plaques and efficiently 
inhibit the progression of atherosclerosis.
Adv. Sci. 2019, 6, 1900172
Figure 1. Illustrations displaying the preparation of RBC/RAP@PLGA for the treatment of atherosclerosis.
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2. Results and Discussion
2.1. Fabrication and Characterization of RBC/RAP@PLGA
Efficient solubilization is critical for hydrophobic RAP to reach 
a sufficient dose in the atherosclerotic lesion. We, therefore, 
generated RAP@PLGA by encapsulating the hydrophobic RAP 
into the hydrophobic “core” of PLGA using a nanoprecipita-
tion method.[36] In contrast to the saturation solubility of RAP 
in water (only ≈2.6 µg mL−1),[37] we were able to load 84.5 µg 
of RAP into 1 mL of PLGA aqueous solution (1 mg  mL−1), 
thereby dramatically increasing its solubilization (more than 
30 times greater than in water). As shown in Table S1 in the 
Supporting Information, drug loading efficiency (LE) and drug 
encapsulation efficiency (EE) of RAP@PLGA were 7.79% and 
84.5%, respectively.
Next, we sought to produce RBC/RAP@PLGA. RAP@
PLGA was wrapped in the extracted RBC vesicles using a 
co-extrusion method.[30,38] We first examined the hydrodynamic 
diameters (Dh) of RBC vesicles, RAP@PLGA and RBC/
RAP@PLGA by dynamic light scattering (DLS). As shown in 
Figure 2A, coating with RBC vesicles increased the mean Dh 
from 81.5 ± 4.5 nm (RAP@PLGA, Polydispersity index (PDI): 
0.087) to 97.4 ± 2.4 nm (RBC/RAP@PLGA, PDI: 0.184). This 
increase in Dh is consistent with the wrapping of the particles 
with RBC membranes, whose normal bilayer thickness is 
7–8 nm.[26,31] Despite the fact that the Dh of RBC vesicles was 
630 ± 28.6 nm (PDI: 0.576), the Dh of RBC/RAP@PLGA was 
close to that of RAP@PLGA, suggesting that the RBC mem-
brane was tightly wrapped around the RAP@PLGA particles. 
Both RAP@PLGA and RBC/RAP@PLGA exhibited homoge-
neous dispersity (Figure S1, Supporting Information). More-
over, RBC/RAP@PLGA showed a relatively constant hydrody-
namic diameter after long-term storage at room temperature, 
indicating its favorable stability properties (Figure S2, Sup-
porting Information). In addition, surface zeta potential 
analysis showed that RAP@PLGA has a zeta potential of 
−21.4 ± 0.6 mV, whereas RBC/RAP@PLGA (−28.7 ± 1.7 mV) 
and RBC vesicles (−31.0 ± 2.7 mV) have similar values 
(Figure 2B). We further analyzed the morphologies of RAP@
PLGA and RBC/RAP@PLGA using transmission electron 
microscope (TEM). Both RAP@PLGA and RBC/RAP@PLGA 
showed a uniform sphere morphology. Moreover, RBC/RAP@
PLGA displayed a clear core–shell nanostructure with a RAP@
PLGA “core” and a RBC membrane “shell” (Figure 2C). These 
results confirm that the RBC membrane was successfully 
coated on the surface of RAP@PLGA, indicating successful 
fabrication of RBC/RAP@PLGA. To further verify the integrity 
of the core–shell nanoparticles, we loaded the PLGA core 
with hydrophobic DiD fluorophore and labeled the RBC 
membrane using DiO. We then incubated RAW264.7, a murine 
macrophage cell line, with these dual-fluorophore-labeled nano-
particles. The resulting fluorescent images showed that most 
of the DiD signal (red, representing the PLGA “core”) was 
co-localized with the DiO signal (green, representing the RBC 
membrane “shell”), indicating an intact “core–shell” structure, 
even after cell internalization (Figure 2D). Moreover, because 
of the exclusive distribution of glycanprotein on the outside of 
cell membranes, the orientation of the RBC membrane on the 
surface of the nanoparticles could be evaluated by quantifi-
cation of glycanprotein.[38,39] As shown in Figure S3 in the 
Supporting Information, the average content of glycoprotein on 
RBC/RAP@PLGA particles is around 93.26% of the equivalent 
amount in free RBC vesicles. This quantification suggests that 
glycoproteins are strongly retained on the outside surface of 
the RBC/RAP@PLGA particles, confirming the “right-side-out” 
orientation of the RBC membrane on the nanoparticles.
The release kinetics of RAP from RAP@PLGA nanoparticles 
and RBC/RAP@PLGA nanoparticles were investigated in PBS 
(pH 7.4) solution to simulate the physiological environment. 
After 72 h incubation in PBS, 35.96% of RAP was released from 
RBC/RAP@PLGA nanoparticles, while 38.52% of RAP was 
released from the RAP@PLGA nanoparticles. When compared 
with the RAP@PLGA nanoparticles, RBC/RAP@PLGA nano-
particles showed a slightly slower RAP release profile (Figure S4, 
Supporting Information), which may be ascribed to the addi-
tional cell membrane bilayer acting as a diffusion barrier. In 
conjunction with the experiments, we developed and numeri-
cally solved a dissolution–diffusion mathematical model of the 
drug release process (see Section 4 for full details of the model 
equations and parameters). We first simulated drug release from 
RAP@PLGA nanoparticles and found an excellent agreement 
between the model and the experimental data. Using the least 
squares method, the model was found to best-fit the data with a 
Damköhler number of Da = 1396, corresponding to a diffusion 
coefficient of order 10−18 m2 s−1, and a normalized solubility 
of 1.66 10 5S = × −  (Figure S5, Supporting Information). Using 
the same values of Da and ,S  we then simulated drug release 
from RBC/RAP@PLGA nanoparticles (Figure S6, Supporting 
Information). We were able to capture the experimental data 
very well when the RBC were described as a thin membrane 
acting as a diffusion barrier, providing additional resistance to 
drug release. The best-fit was found for a normalized mem-
brane resistance of Γ = 173. These simulations confirm that 
drug release from RAP@PLGA and RBC/RAP@PLGA nano-
particles is well described by a dissolution–diffusion mecha-
nism. In general, the RAP release profile from RBC/RAP@
PLGA nanoparticles suggested their good potential to be used 
for sustained drug release.
2.2. RBC/RAP@PLGA Nanoparticles Display Immune-Evasive 
Properties In Vitro and In Vivo
Accumulating evidence in the literature suggests that cell 
membrane proteins are critical for the immune-evasive func-
tion of RBCs.[40,41] Thus, we first studied if RBC/RAP@PLGA 
maintained membrane proteins of RBCs. As shown in Figure 3A, 
SDS-PAGE suggested that RBC ghosts, RBC vesicles, and RBC/
RAP@PLGA were highly consistent in protein bands, revealing 
that almost all membrane proteins were retained throughout the 
RBC/RAP@PLGA fabrication. Evidence in the literature sug-
gests that the ability of RBCs to evade macrophage recognition is 
ascribed to a cooperative contribution of diverse functional mem-
brane proteins on the RBC membrane surface. Among them, 
CD47, widely expressed on the surface of the RBC membrane, 
plays a key role in regulating phagocytosis by macrophages by 
bonding with the SIRP-α receptor.[41] Therefore, we tested for 
Adv. Sci. 2019, 6, 1900172
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CD47 expression on RBC ghosts, RBC vesicles, and RBC/RAP@
PLGA using western blot analysis. The results clearly show the 
presence of CD47 on RBC/RAP@PLGA (Figure 3B).
To study the dynamic uptake of RBC/RAP@PLGA by 
macrophages, we incubated DiD loaded nanoparticles with 
RAW264.7 cells and performed time-lapse studies using confocal 
laser scanning microscopy (CLSM). As shown in Figure 3C, 
both DiD@PLGA and RBC/DiD@PLGA were engulfed by 
macrophages in a time-dependent manner. However, when 
compared with DiD@PLGA, phagocytosis of RBC/DiD@PLGA 
by macrophages was noticeably reduced. We further quantified 
the distinctive kinetic uptake using flow cytometry (Figure 3D,E) 
and consistently found that the cellular uptake of DiD@PLGA 
and RBC/DiD@PLGA were both time-dependent. However, 
the internalization signal of RBC/DiD@PLGA was significantly 
lower than that of DiD@PLGA, as evidenced by 1.6-, 2.6-, 3.3-, 
and 2.9-fold decreases at 1, 2, 4, and 8 h incubation, respectively 
(Figure 3F). The CLSM images and fluorescence activated cell 
sorting (FACS) analysis collectively suggested that coating nano-
particles with RBC membranes inhibited macrophage-mediated 
Adv. Sci. 2019, 6, 1900172
Figure 2. A) The Dh and B) zeta potential of RBC vesicles, RAP@PLGA and RBC/RAP@PLGA (n = 3, mean ± SD). C) TEM images of RAP@PLGA and 
RBC/RAP@PLGA (scale bar = 100 nm). D) CLSM images of RBC/DiD@PLGA internalization by cells, the nucleus (blue), RBC “shell” (green) and 
PLGA “core” (red) (scale bar = 5 µm).
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phagocytosis. The reduced uptake 
of RBC membrane coated nano-
particles was probably due to the 
immune-evasive properties of the 
RBC membrane proteins.
Compared with unmodi-
fied nanoparticles and even the 
poly(ethylene glycol) modified 
nanoparticles, RBC membrane-
coated nanoparticles have been 
reported to show an increased 
ability to evade phagocytosis 
by macrophages and systemic 
clearance, resulting in longer 
blood-circulation time.[26,28–30] Sub-
sequently, we utilized C57BL/6 
mice as a model to investigate the 
pharmacokinetics of RBC/DiD@
PLGA nanoparticles. After tail vein 
injection of DiD@PLGA or RBC/
DiD@PLGA, blood was drawn 
at a predetermined time interval 
from the tail vein to measure the 
fluorescence intensity. Compared 
with DiD@PLGA nanoparticles, 
RBC/DiD@PLGA nanoparticles 
showed greatly prolonged blood 
circulation, attributed to the RBC 
membrane cloaking (Figure 3G). 
After injecting for 24 and 48 h, 
the RBC@PLGA and DiD@PLGA 
nanoparticles exhibited about 31% 
and 17% overall retention in blood, 
respectively. However, the bare 
PLGA nanoparticles (DiD@PLGA) 
showed negligible signal after 4 h 
injection, indicating rapid clear-
ance. These results demonstrate 
that the RBC membrane coated 
nanoparticles can indeed prolong 
the blood circulation time.
2.3. In Vitro Macrophage Inhibition
Since macrophage cells play an 
important role in atherosclerosis 
progression, we examined if 
RAP loaded nanoparticles inhibit 
proliferation of RAW264.7 cells, 
a murine macrophage cell line. 
Consistent with previous studies, 
free RAP inhibited macrophage 
viability in a dose-dependent 
manner with an IC50: ≈5 µg mL−1 
(Figure S7, Supporting Infor-
mation). Moreover, at the same 
dose, RAP@PLGA and RBC/
RAP@PLGA are comparable in 
Adv. Sci. 2019, 6, 1900172
Figure 3. Membrane protein characterization and immune evasive properties in vitro and in vivo. A) Proteins 
in RBC ghosts, RBC vesicles, and RBC/RAP@PLGA were characterized by polyacrylamide gel electro-
phoresis. B) Western blot analysis of CD47 in RBC ghost, RBC vesicles, and RBC/RAP@PLGA. C) CLSM 
images of DiD@PLGA and RBC/DiD@PLGA phagocytosed by RAW264.7 macrophages at different time 
points (scale bar = 10 µm). Cellular uptake of D) DiD@PLGA and E) RBC/DiD@PLGA in RAW264.7 cells 
by flow cytometry. F) Quantification of cellular uptake of DiD@PLGA and RBC/DiD@PLGA in RAW264.7 
macrophages at different time points (n = 3). G) Pharmacokinetic studies of RBC/DiD@PLGA and DiD@
PLGA in C57BL/6 mice, (n = 5). *p < 0.05, **p < 0.01, and ***p < 0.001. ns, no significance.
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inhibition of macrophage proliferation. The slightly more potent 
antiproliferative activity of free RAP might be ascribed to the 
slower RAP release from PLGA.
2.4. In Vivo Target Atheroprotective Effect
To study in vivo antiatherosclerosis effects, we first investigated 
the accumulation of the nanoparticles within atherosclerotic 
plaques. Atherosclerosis was induced in ApoE−/− mice by feeding 
with a high-fat diet (HFD) for 10 weeks. We then administered 
these mice with DiD@PLGA or RBC/DiD@PLGA through 
tail vein injection. Aortas were harvested 24 h postinjection. 
As shown by ex vivo imaging in Figure 4A, RBC/DiD@PLGA 
clearly accumulated in atherosclerotic plaque areas. Strong flu-
orescence signals were clearly observed at the aortic arch and 
abdominal aorta, areas prone to atherosclerosis as a result of 
abnormal flow patterns. By contrast, the DiD@PLGA group 
showed significantly lower signals in atherosclerotic plaque 
compared with the RBC/DiD@PLGA group (Figure 4B). In 
Adv. Sci. 2019, 6, 1900172
Figure 4. A) The ex vivo fluorescence images of the aorta and B) quantitative data of fluorescence signals accumulated in the aorta of ApoE−/− mice after 
injection of 5% sucrose (Control), DiD@PLGA, and RBC/DiD@PLGA, n = 3, mean ± SD, *p < 0.05 and ***p < 0.001. C) CLSM images of accumulated 
RBC/DiD@PLGA in atherosclerotic plaques of the aortic root section in ApoE−/− mice. Scale bar = 100 µm.
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addition, immunofluorescence histological examination of the 
aortic root section demonstrated that red fluorescent RBC/
DiD@PLGA accumulated in the atherosclerotic plaque, while 
little DiD@PLGA was observed in the atherosclerotic plaque 
(Figure 4C). These results demonstrated that the RBC mem-
brane modification enhanced atherosclerotic plaque targeting in 
vivo. In that case, once RBC/RAP@PLGA nanocomplexes had 
accumulated in the atherosclerotic lesion, RAP was continuously 
released from RBC/RAP@PLGA, thereby increasing the local 
drug concentration to inhibit the proliferation of macrophages 
and vascular smooth muscle cells (SMCs), and the inflammatory 
responses in the lesion, and finally significantly attenuating the 
progression of atherosclerosis. In brief, RBC/RAP@PLGA with 
targeted drug delivery provided a prerequisite for the subse-
quent local drug release and efficient atherosclerosis manage-
ment, resulting from decreased phagocytosis and sustained 
local drug release, respectively.
Having confirmed the significantly increased accumulation 
of RBC membrane-coated nanoparticles within plaques, we 
assessed the antiatherosclerosis potential of free RAP, RAP@
PLGA, and RBC/RAP@PLGA in ApoE−/− mice. After treatment 
for one month, we acquired aortas from the aortic arch to 
the iliac bifurcation and stained with ORO. Control aortas 
(5% sucrose injection) clearly showed atherosclerotic lesions 
by en face ORO staining (Figure 5A). Treatment with free drug 
or RAP@PLGA reduced the lesion area of the plaque. En face 
quantification of the ORO stained plaque showed that the area 
ratio of plaque to the whole aorta was decreased from 20.13% 
to 17.8% and 14.84% after treatment with free drug and RAP@
PLGA, respectively (Figure 5B). RBC/RAP@PLGA treatment 
achieved significantly higher therapeutic efficacy as evidenced 
by a plaque ratio of 6.24%, confirming the profound inhibition 
of atherosclerosis progression.
The cross-sections of ORO-stained aortic roots further con-
firmed the extent of plaque in the vascular lumen (Figure 5C). 
Compared with the value of 47.95% in the control group, the 
average area ratio of plaque to vascular lumen decreased to 
42.42%, 40.48%, and 31.34% after treatment with free drug, 
RAP@PLGA and RBC/RAP@PLGA, respectively (Figure 5D). 
These results suggest that RBC/RAP@PLGA can effectively 
attenuate the progression of atherosclerosis.
Next, we detected the composition of atherosclerotic plaque 
in aortic root sections by immunohistochemistry staining. The 
necrotic areas in the aortic roots were detected by Toluidine 
blue staining. As shown in Figure 6A, the control group exhib-
ited large necrotic areas with substantial cholesterol crystals, 
indicating advanced lesions. After treating with RBC/RAP@
PLGA, the necrotic area was significantly decreased. Quanti-
tative analysis revealed that, compared to the control group, 
the average necrotic area was decreased to 8.56%, 5.00%, and 
1.52% in response to free RAP, RAP@PLGA, and RBC/RAP@
PLGA treatment, respectively (Figure 6B). The increased col-
lagen produced by hyperplasia smooth muscle cells leads to 
the enlargement of the plaque areas, which could further 
Adv. Sci. 2019, 6, 1900172
Figure 5. Atherosclerosis treatment by RBC/RAP@PLGA in ApoE−/− mice. A) The en face ORO stained images of aortas from each group (a, Control; 
b, Free drug; c, RAP@PLGA; d, RBC/RAP@PLGA). B) Quantitative data of the atherosclerotic plaque area. C) ORO-stained images of aortic roots 
sections. (a, Control; b, Free drug; c, RAP@PLGA; d, RBC/RAP@PLGA; scale bar = 500 µm). D) Quantitative data of the atherosclerotic plaque area 
in the aortic root sections. n = 5, mean ± SD, *p < 0.05, **p < 0.01, and ***p < 0.001, ns, no significance.
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narrow the vascular lumen.[42] We tested the content of col-
lagen in plaque areas using Masson’s trichrome staining 
(Figure 6C,D). Compared to the control, free RAP, RAP@
PLGA, and RBC/RAP@PLGA effectively decreased the con-
tent of collagen.
Evidence from the literature indicates that macrophages and 
vascular smooth muscle cells (SMCs) play a key role in the 
initiation and progression of atherosclerotic inflammation.[42–44] 
Immunohistochemistry analyses for CD68 (a macrophage 
marker) (Figure 7A,B) and α-SMA (a SMC marker) 
(Figure 7C,D) showed that the number of macrophages and 
SMCs dramatically decreased in the atherosclerotic plaque 
area after treating with nanotherapies, particularly after treat-
ment with RBC/RAP@PLGA. These findings confirmed that 
RAP delivered using nanoparticles could more effectively 
inhibit the progression of atherosclerosis and suppress 
luminal narrowing due to the growth inhibition of SMCs and 
blockade of macrophage infiltration. Matrix metalloprotein-
ases (MMPs), mainly secreted by macrophage-derived foam 
cells in atherosclerosis, may well degrade the extracellular 
matrix within plaque, resulting in plaque rupture. Indeed, the 
level of MMP-9 in plaque lesions has been positively associ-
ated with the stability of vulnerable plaques.[45,46] The immu-
nohistochemistry analyses for MMP-9 showed a notably lower 
level of MMP-9 in plaque areas from mice treated with RBC/
RAP@PLGA (Figure S8, Supporting Information). This indi-
cated that RBC/RAP@PLGA may stabilize atherosclerotic 
plaques. Endothelial cells (ECs) play an important role in 
vascular homeostasis. Dysfunction of the vascular endothe-
lium of the arterial vasculature is an important contributor 
to the progression of atherosclerotic vascular diseases.[47] The 
immunohistochemistry analyses for CD31 (a marker for ECs) 
showed notable expression of CD31 in the vascular endothe-
lium of the aortas from mice treated with RBC/RAP@PLGA 
(Figure S9, Supporting Information). This indicated that RBC/
RAP@PLGA treatment not only maintains the integrity of the 
vascular endothelium, but also is unlikely to be toxic to ECs. 
Collectively, our results demonstrated that RBC/RAP@PLGA 
more potently attenuated the development of atherosclerotic 
plaque compared to RAP@PLGA.
2.5. Biosafety Assessment
To assess biosafety, adverse effects were studied after treatment 
for one month. There was no significant difference in body 
weight of mice between the various treated groups (Figure 8A). 
Moreover, no obvious difference in the organ index of heart, 
liver, spleen, lung, and kidney was observed, suggesting no 
significant toxicity to the main organs (Figure 8B). The results 
of hematoxylin-eosin (H&E) staining showed that no distin-
guishable change could be found in the main organs, which 
further confirmed their biocompatibility (Figure 9). In addition, 
the blood biochemical assays of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), creatinine (CREA), 
and blood urea nitrogen (UREA) were at normal levels, which 
Adv. Sci. 2019, 6, 1900172
Figure 6. Immunohistochemistry analyses of aortic root sections from ApoE−/− mice after different treatments. A) The images of the necrotic areas 
stained by Toluidine blue (scale bar = 500 µm). B) Quantitative data of the necrotic areas in the aortic root sections. C) The images of collagen in 
the plaque areas stained by Masson’s trichrome (scale bar = 500 µm). D) Quantitative data of the content of collagen in aortic root sections. n = 5, 
mean ± SD, *p < 0.05, **p < 0.01, and ***p < 0.001, ns, no significance.
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Figure 7. Immunohistochemistry staining of aortic root sections from ApoE−/− mice after different treatments. Representative images of immunohis-
tochemistry staining with antibodies to A) CD68 and C) α-SMA (scale bar = 500 µm). Quantitative data of B) the relative number of macrophages and 
D) SMCs in plaque areas of the aortic root sections. n = 5, mean ± SD, *p < 0.05, **p < 0.01, and ***p < 0.001, ns, no significance.
Figure 8. Toxicological evaluations after one month of treatment. A) The body weight of ApoE−/−mice during various treatments. B) The organ index. 
C–F) The biochemical assays of hepatic and kidney functions. AST, aspartate aminotransferase; ALT, alanine aminotransferase; URN, blood urea 
nitrogen; and CRE, creatinine. n = 5, mean ± SD.
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indicated that the functions of the liver and kidney were not 
impaired by the treatment (Figure 8C–F). Routine blood exami-
nation implied that levels of RBCs, white blood cells (WBCs), 
platelets (PLT), and hemoglobin (HGB) did not vary between 
different mice (Figure S10A–D, Supporting Information). Also, 
the levels of high density lipoprotein (HDL), low density lipo-
protein (LDL), triglyceride (TG), and total cholesterol (TC) did 
not change significantly during the treatment (Figure S10E–H, 
Supporting Information). Accordingly, RBC/RAP@PLGA did 
not induce significant adverse effects in long-term treatment, 
indicating its potential as a safe candidate for chronic vascular 
disease therapy.
3. Conclusion
In summary, we developed biomimetic nanocomplexes, 
consisting of RAP-loaded PLGA nanoparticles as the core 
and RBC membranes as a cloak, for effective treatment of 
atherosclerosis. The resulting biomimetic nanocomplexes 
(RBC/RAP@PLGA) showed favorable properties including 
controllable size, negative charge, sustained drug-release 
kinetics, effective inhibition of macrophage proliferation in 
vitro, and long blood circulation in vivo. Mathematical mode-
ling confirmed that drug release from RAP@PLGA and RBC/
RAP@PLGA nanoparticles is well-described by a dissolution–
diffusion mechanism. In ApoE−/− mice which induced 
atherosclerosis by a high-fat diet, RBC membrane cloaked 
nanoparticles accumulated in established atherosclerotic 
plaques. Compared with RAP@PLGA, RBC/RAP@PLGA 
significantly delayed the progression of atherosclerosis after 
treatment for one month. Furthermore, the biomimetic nano-
complexes displayed a desirable safety profile without signifi-
cant side effects, even after long-term administration in mice. 
Overall, for the first time, our work has demonstrated the 
therapeutic advantages of RBC membrane cloaked nanoparti-
cles for the treatment of atherosclerosis. These nanoparticles 
may be considered as a feasible candidate for a new class of 
safe and effective targeted drug delivery system for chronic 
inflammatory disease management.
Adv. Sci. 2019, 6, 1900172
Figure 9. H&E stained images of main organs from mice after various treatments for one month. All the micrographs were acquired at 40× magnification.
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4. Experimental Section
Materials: Rapamycin (RAP) and PLGA (MW.90000, 50:50) were 
purchased from Dalian Meilun Biotechnology Co. Ltd. (Dalian, Chia). 
1,19-dioctadecyl-3,3,39,39-tetramethylindodicarbocyanine perchlorate 
(DiD) was purchased from Biotium Inc. (Fremont, US). DiO, DAPI, and 
cell total protein extraction kits were supported by Beyotime Institute 
of Biotechnology (Jiangsu, China). Mouse Glycoprotein ELISA kit was 
purchased from Wuhan ColorfulGene Biological Technology Co. Ltd. 
(Wuhan, China).
Preparation of RBC Vesicles: RBC vesicles were prepared following a 
previously reported method with minor modifications.[30] Whole blood was 
obtained from C57BL/6 mice (eight weeks) via orbital sinus puncture using 
EDTA spray-coated tubes (Labtub, China). Then, the blood was centrifuged 
at 2500 rpm for 5 min at 4 °C (Centrifuge 5418 R, Eppendorf, Germany) 
and the serum were carefully removed. The collected RBCs were washed 
with phosphate buffered saline (PBS, pH = 7.4) three times to remove the 
residual serum. The washed RBCs were resuspended in dilute 0.25 × PBS 
(pH = 7.4) containing 0.2 × 10−3 m EDTAK2 for 30 min at 4 °C to induce 
membrane rupture. Subsequently, the RBCs solution was centrifuged at 
10 000 rpm for 5 min at 4 °C, and the supernatant was removed. After 3 
wash-centrifugation cycles using PBS, RBC ghosts (RBCG) were collected as 
the pink precipitation. To obtain RBC vesicles, RBCG were resuspended in 
water, and then ultrasonicated for 15 min using the sonicator bath (FS30D, 
42 kHz, 100 W). The harvested RBC vesicles were stored in water at 4 °C.
Preparation of Rapamycin-Loaded PLGA (RAP@PLGA) Nanoparticles: 
RAP@ PLGA nanoparticles were prepared by a nanoprecipitation process.[36] 
Briefly, RAP (1 mg) and PLGA (10 mg) were dissolved into dimethyl 
sulfoxide (DMSO) (1 mL). The mixture was precipitated by adding dropwise 
into 3 mL water with gentle stirring, and further dialyzed using dialysis 
bag (molecular weight cut-off, MWCO: 3500 Da) against water to remove 
the free RAP and DMSO. The solutions of RAP@PLGA nanoparticles 
were collected, and preserved at 4 °C. To prepare the florescence labeled 
nanoparticles, 0.1 wt% DiD was loaded in PLGA as per the former method.
Preparation of RBC Membrane Cloaking RAP@PLGA (RBC/RAP@
PLGA) Nanoparticles: RBC vesicles and RAP@PLGA nanoparticles were 
fused to prepare RBC/RAP@PLGA by an extrusion method.[38] Briefly, 
RBC vesicles (obtained from 500 µL of whole blood) and RAP@PLGA 
(containing 2 mg of PLGA) were mixed, and ultrasonicated for 2 min 
using the bath sonicator (FS30D, 42 kHz, 100 W). Then, the mixture 
solution was extruded using an Avestin mini-extruder (Avestin, LF-1, 
Canada) through a 200 nm polycarbonate porous membrane for 10 times 
to harvest the RBC/RAP@PLGA.
Characterization of Nanoparticles: The size and zeta potential of RAP@
PLGA, RBC vesicles and RBC/RAP@PLGA were determined using a 
Malvern Zetasizer Nano ZS unit (Nano ZS 90, Malvern, UK) with a He-Ne 
laser (λ = 633 nm) at a scattering angle of 90° at 25 °C. A drop of RAP@
PLGA or RBC/RAP@PLGA nanoparticle solution at a concentration 
of 150 µg mL−1 was dropped onto a copper mesh, and stained by 1% 
phosphotungstic acid. Subsequently, the morphology of RAP@PLGA and 
RBC/RAP@PLGA were visually observed using a transmission electron 
microscope at 200 kV (TEM, JEM-2100F, JEOL, Japan).
Characterization of Proteins: The membrane proteins were 
characterized by polyacrylamide gel electrophoresis (SDS-PAGE). The 
membrane protein of RBC ghosts, RBC vesicle, and RBC/RAP@PLGA 
were extracted by the cell total protein extraction kits (Beyotime). The 
extracted membrane proteins were run on 12% SDS-PAGE gel in a 
running buffer using BIO-RAD electrophoresis system at 70 V for 0.5 h 
and then at 140 V for 1 h. Finally, the SDS-PAGE gel was stained with 
SimplyBlue for visualization. CD47 was analyzed by western blot (WB). 
The RBC ghosts, RBC vesicles, and RBC/RAP@PLGA were lysed with 
lysis buffer containing 1% phosphatase inhibitors (Beyotime) for 15 min 
at 4 °C. The lysis solution was centrifuged at 12 000 rpm for 10 min 
at 4 °C. The supernatant was collected, and the protein concentration 
was measured using the BCA protein assay kit (Beyotime). The detailed 
protocol of WB has been described previously.[48] Briefly, an equal 
amount of protein from each sample was separated by 12% SDS-PAGE, 
and transferred onto a polyvinylidene difluoride membrane (PVDF, 
Millipore, USA). The transferred PVDF membranes were blocked with 
5% milk, and then incubated with primary antibodies against CD47 
(Anti-CD47 antibody, ab175388, abcam) for 12 h at 4 °C. Finally, the 
membranes were incubated with HRP-conjugated secondary antibodies 
and observed by ChemiDoc- XRS imaging system (Bio-Rad).
Identification of Membrane Orientation of RBC/RAP@PLGA: To identify 
the membrane orientation of RBC/RAP@PLGA, the glycoprotein content 
in the RBC/RAP@PLGA nanoparticles was quantified as previously 
reported.[38,39] Briefly, 1 mL of solution of RBC/RAP@PLGA (1 mg mL−1) 
was incubated with 5 µg of trypsin at room temperature for 2 h to initiate 
trypsinization. Then, the samples were centrifuged at 8000 rpm for 
5 min, and the supernatant was collected to quantify glycoprotein using a 
Mouse Glycoprotein ELISA Kit following the manufacturer’s instructions.
Drug Loading and In Vitro Drug Release Study: To calculate the loading 
efficiency of RAP, RAP@PLGA lyophilized powder was dissolved in 
DMSO, and the absorbance measured by UV–vis spectrophotometer 
(DU730, Beckman Coulter) at 280 nm. According to the pre-established 
standard curve of RAP in DMSO, the drug loading efficiency (LE) and drug 
encapsulation efficiency (EE) were calculated as the following equations
LE % 100%RAP
PLGA RAP
M
M M( ) = + ×  (1)
EE % 100%RAP
added
M
M( ) = ×  (2)
in which MRAP is the mass of RAP loaded in the nanoparticles, MPLGA is the 
mass of polymer in the formulation and Madded is the mass of added RAP.
To study the drug release profile in vitro, RAP@PLGA and RBC/
RAP@PLGA nanoparticle solutions (1 mg mL, 1 mL) were added to 
disposable dialysis cups (Slide-A-Lyzer MINI Dialysis Units, MWCO: 
3500 Da, Thermo Scientifc) in PBS (10 mL). At different time points, the 
external drug release buffers were collected and an equivalent amount of 
PBS was added. The cumulative amount of RAP released was quantified 
by high performance liquid chromatography (HPLC).
Mathematical Modeling of In Vitro Drug Release: A mathematical model 
was developed to describe RAP release from the RAP@PLGA and RBC/
RAP@PLGA nanoparticles. Given that RAP was extremely poorly soluble, it 
was proposed that dissolution in the release medium would be an important 
factor in determining the release rate. A homogeneous distribution of drug 
encapsulated in the PLGA initially at some concentration B was assumed 
and it was noted that there was no significant degradation of PLGA over 
the 72 h studied. Further, a radially symmetric model was assumed for 
the nanoparticles of radius R and the spatial and temporal coordinates 
were denoted by r and t, respectively. When exposed to the PBS release 
medium, the nanoparticles become wetted and a dissolution process 
ensues, converting immobile drug (of concentration b(r, t)) to dissolved 
drug (of concentration c(r, t)). When dissolved, the drug was able to diffuse 
through the nanoparticle with diffusion coefficient D. Following previous 
work,[49] the dissolution process was modeled through a nonlinear reaction 
whereby dissolution occured at some rate Kb(r, t)2/3 (K constant) and in 
proportion to the distance between the dissolved drug concentration and 
the maximum dissolved drug concentration, denoted by S, the solubility. 
The exponent 2/3 arose based on the assumption that the surface area of 
undissolved drug was proportional to the volume (for more details, the 
reader is referred to Frenning[50]). The model was then given by
, 0 , 02/3b
t
Kb S c r R t( )∂∂ = − − < < >  (3)
2 , 0 , 0
2
2
2/3c
t
D c
r r
c
r
Kb S c r R t( )∂∂ =
∂
∂ +
∂
∂



 + − < < >  (4)
c
r
r t0, 0, 0
∂
∂ = = >  (5)
c r R t0, , 0= = >  (6)
b B c r R t, 0, 0 , 0= = < < =  (7)
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The boundary conditions given by Equations (5) and (6) represented 
symmetry and sink conditions, respectively. The model given by 
Equations (3–7) was utilized to describe drug release from the RAP@
PLGA nanoparticles. In order to model drug release from the RBC/
RAP@PLGA nanoparticles, it was supposed that the RBCs act as a thin 
membrane and, therefore, the boundary condition (6) was modified to 
obtain
D c
r
P c r R t, , 0−
∂
∂ = = >  (8)
where P provides a measure of the membrane resistance.
The model represents a set of nonlinear coupled partial differential 
equations. To solve the equations, an approach similar to the method 
we previously described was adopted.[49] Briefly, the equations were 
discretized in space and then Matlab’s ODE45s solver for stiff 
problems was used to solve the resulting set of coupled ordinary 
differential equations. For numerical convenience, the model was non-
dimensionalized by letting
t
t
T
r
r
R
c
c
B
b
b
B
S
S
B
, , , ,
D
= = = = =  (9)
where TD =  R2/D was the timescale for diffusion. The resulting 
nondimensional model for RAP@PLGA (see Supporting Information) 
consisted of only two nondimensional parameters: i) the normalized 
solubility S , and ii) the Damköhler number Da = KB2/3 R2/D, which 
characterized the rate of dissolution to the rate of diffusion. The 
nondimensional model for RBC/RAP@PLGA contained a further 
nondimensional parameter, Γ = R P/D, which characterized the 
membrane resistance.
Co-Localization Study: RAW 264.7 cells were cultured in DMEM 
medium containing 10% fetal bovine serum (FBS) at 37 °C with 
5% CO2. Thereafter, 100 µg of RBC/DiD@PLGA was added to RAW 
264.7 cells, in which the RBC membrane of RBC/DiD@PLGA was 
labeled by DiO. After incubation for an additional 2 h, the cells 
were washed with PBS three times, and fixed with paraformaldehyde 
(4% in PBS) for 30 min at room temperature. Then, the nucleus of 
RAW 264.7 cells were stained with 4′,6-diamidino-2-phenylindole 
(DAPI). The confocal laser scanning microscopy (SP8, Leica, 
Germany) images of the cells were obtained under 405, 488, and 
644 nm filters, respectively.
Nanoparticles Uptake by Macrophages: RAW264.7 cells were seeded in 
12-well plates at a density of 1 × 105 cells per well in 1 mL of DMEM 
medium containing 10% FBS, and cultured at 37 °C with 5% CO2 for 
24 h. 100 µg of DiD@PLGA and RBC/DiD@PLGA were added. After 
incubation for different times, the cells were washed with PBS, and 
fixed with paraformaldehyde (4% in PBS). The nuclei of the cells were 
stained with DAPI. The cells were observed using CLSM. For cell uptake 
quantification, RAW264.7 cells without DAPI staining were digested, and 
the fluorescent intensity of these samples was subsequently measured 
by fluorescence activated cell sorting.
Inhibition of Proliferation of Macrophages In Vitro: RAW264.7 cells were 
seeded in a 96-well plate (105 cells per well), and cultured in DMEM 
medium containing 0.5% FBS for 12 h. Then, the cells were incubated 
with various doses of free RAP, RAP@PLGA, and RBC/RAP@PLGA for 
24 h, respectively. The cell viability was quantified by CCK-8 assay.
Animals: Male C57BL/6 mice and male apolipoprotein E-deficient 
(ApoE−/−) mice (25–30 g, eight-week old) were obtained from the Third 
Military Medical University in Chongqing, China. All the animal care 
and experimental protocols were carried out with review and approval 
from the Laboratory Animal Welfare and Ethics Committee of the Third 
Military Medical University.
In Vivo Pharmacokinetics Study: The experiments utilized adult male 
C57BL/6 mice weighing 25 ± 2 g as the in vivo model. To study the half-
life of RBC/DiD@PLGA in circulation, 150 µL of DiD@PLGA or RBC/
DiD@PLGA was injected into the mice through the tail vein. 20 µL of 
blood was collected at 1, 5, 15, 30 min, and 1, 2, 4, 6, 18, 24, 48, and 
60 h after injection. The blood samples were diluted with 40 µL PBS 
contained 0.2 × 10−3 m EDTA2K in 96-well plates, and the fluorescence 
intensity was measured by fluorescence microplate reader (SpectraMax 
Gemini EM, USA).
Accumulation of Nanoparticles in Atherosclerotic Plaques of ApoE−/− Mice: 
ApoE−/− mice were fed with a high fat diet (HFD) for 10 weeks. 150 µL 
DiD@PLGA or RBC/DiD@PLGA was injected through the tail vein. 
After 24 h, mice were euthanized, perfused with PBS containing 4% 
paraformaldehyde and heparin sodium, and the aorta was isolated 
for imaging and fluorescence quantification using a Xenogen IVIS 
200 system. The aortas of 5% sucrose-treated mice were used 
as the control group to subtract the tissue auto-fluorescence. 
Immunofluorescence staining of the cross-sections of the aortic roots 
was performed as previously described. The frozen sections of carotid 
roots were incubated with 5% serum. Then, the sections were incubated 
with anti-CD68 antibody overnight at 4 °C, followed by Donkey anti-
rabbit IgG H&L for 2 h at room temperature. Samples were stained with 
DAPI to show the cell nucleus. The sections were observed by CLSM.
Treatment of Atherosclerosis in ApoE−/− Mice: Twenty ApoE−/− mice were 
randomized into 4 groups (5 mice per group), and given the HFD for 
10 weeks. Then, the mice were subjected to the different treatments for 
one month. The mice injected with 5% sucrose served as the control 
group, while the other three groups were treated with either free drug, 
RAP@PLGA or RBC/RAP@PLGA at a dose of 0.7 mg kg−1 of RAP every 
three days via tail vein injection. The body weight of mice was monitored 
during the treatment.
Quantitative Analysis of Atherosclerotic Plaques after Treatment: After 
treatment for 30 d the aortas, from the heart to the iliac bifurcation, 
from ApoE−/− mice were harvested. Aortas were fixed by perfusion with 
paraformaldehyde (4% in PBS). After removing the periadventitial tissue, 
aortas were dissected longitudinally, and then stained with Oil Red O 
(ORO) to quantify the plaque area. The extent of atherosclerotic plaque 
at the aortic root was also determined by ORO staining. Quantitative 
analysis of atherosclerotic plaque areas was performed using Nis-
Elements BR 3.2 software (Nikon, Japan).
Histology and Immunohistochemistry Staining of the Aortic Root: The 
aortic roots were fixed with paraformaldehyde (4% in PBS) for 1 h, and then 
prepared to paraffin sections. After deparaffinizing, Masson’s trichrome 
and Toluidine blue staining were used to quantify the content of collagen 
and the necrotic core, respectively. For immunohistochemistry analysis, 
the activity of the endogenous peroxidase was inhibited by immersion into 
3% hydrogen peroxide and 100% methanol for 20 min. Then, the sections 
were blocked with 5% bovine serum albumin in PBS for 60 min. Antibodies 
to CD68, α-smooth muscle actin (α-SMA), matrix metalloproteinase-9 
(MMP-9) or CD31 were incubated for quantification of macrophage, 
MMP-9, smooth muscle cells (SMCs) and endothelial cells (ECs) 
respectively. Quantitative analysis of histology and immunohistochemistry 
were performed using the Nis-Elements BR 3.2 software (Nikon, Japan). 
Sections of the main organs including heart, liver, spleen, lung, and kidney 
were also analyzed by hematoxylin-eosin (HE) staining.
Complete Blood Biochemistry and Routine Analysis: Blood was collected 
in EDTA2K spray-coated tubes after treatment for one month, and 
immediately analyzed using an automated hematology analyzer (Sysmex 
KX-21, Sysmex Co., Japan). The concentrations of alanine aminotransferase, 
aspartate aminotransferase, creatinine, blood urea nitrogen , high density 
lipoprotein, low density lipoprotein, triglyceride, and total cholesterol in 
plasma from different treatments were quantified by an automated analyzer 
platform (Roche Cobas C501, Roche Co., Switzerland).
Statistical Analyses: The data obtained are reported as the mean ± 
standard deviation in this study. GraphPad Prism Version 6.0 software 
(GraphPad, USA) was used for the statistical analysis. One-way analysis 
of variance (ANOVA) by Tukey’s test was used to reveal differences 
among the groups. The difference significance levels were set at 
*p < 0.05, **p < 0.01, and ***p < 0.001.
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